Johnson & Johnson Stock

$173.33

1.05% yesterday

NYSE, Aug 08, 10:09 pm CET

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Johnson & Johnson Stock price

$173.33

+25.30 17.09% 5Y

NYSE, Closing price Fri, Aug 08 2025

+1.80 1.05%

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$417.4b

Enterprise Value

$449.3b

Net debt

$31.9b

Cash

$18.9b

Shares outstanding

2.4b

Valuation (TTM | estimate)

P/E

18.5 | 16.2

P/S

4.6 | 4.4

EV/Sales

5.0 | 4.8

EV/FCF

24.2

P/B

5.3

Dividends

DPS

$4.91

Yield 1Y | 5Y

2.8% | 2.8%

Growth 1Y | 5Y

4.5% | 5.5%

Payout 1Y | 3Y

84.8% | 53.6%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$90.6b | $94.3b

EBITDA

$30.7b | $35.1b

EBIT

$23.2b | $30.9b

Net Income

$22.7b | $25.8b

Free Cash Flow

$18.5b

Growth (TTM | estimate)

Revenue

4.7% | 6.2%

EBITDA

-4.7% | 13.9%

EBIT

-6.9% | 31.5%

Net Income

-40.4% | 83.7%

Free Cash Flow

-8.6%

Financial Health

Equity Ratio

39.7%

Return on Equity

19.7%

ROCE

16.7%

ROIC

11.8%

Debt/Equity

0.6

EPS

$9.4

FCF per Share

$7.7

Short interest

0.8%

Employees

138k

Rev per Employee

$640.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

29 Analysts have issued a Johnson & Johnson forecast:

13x Buy

45%

16x Hold

55%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Johnson & Johnson forecast:

Buy

45%

Hold

55%

Analyst Estimates with Stock Price Targets

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	90,627 90,627	5% 5% 100%
- Direct Costs	29,015 29,015	10% 10% 32%
Gross Profit	61,612 61,612	2% 2% 68%
- Selling and Administrative Expenses	22,932 22,932	4% 4% 25%
- Research and Development Expense	17,034 17,034	14% 14% 19%
EBITDA	30,665 30,665	5% 5% 34%
- Depreciation and Amortization	7,457 7,457	3% 3% 8%
EBIT (Operating Income) EBIT	23,208 23,208	7% 7% 26%
Net Profit	22,661 22,661	40% 40% 25%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Johnson & Johnson Stock News

Positive

The Motley Fool

●

about 5 hours ago

3 Stocks Retirees Should Absolutely Love

Priorities change as you enter new seasons of life. That's especially true for your retirement years.

Positive

Seeking Alpha

●

2 days ago

August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys

Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbac...

Positive

Seeking Alpha

●

5 days ago

Why Johnson & Johnson Stock Still Has Room To Run

On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise. Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $90...

More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office	United States
CEO	Joaquin Duato
Employees	138,100
Founded	1887
Website	www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now